Amycretin: The GLP-1/Amylin Dual Agonist Rewriting Weight Loss Science in 2026

Amycretin is a synthetic fusion peptide developed by Novo Nordisk that covalently links a GLP-1 receptor agonist moiety to an amylin receptor agonist moiety within a single molecule. This is fundamentally different from co-administering two separate drugs (as in the CagriSema combination approach) — the unified molecule is designed to activate both receptor systems with a single pharmacokinetic profile, dosed once weekly in an oral tablet formulation.

The GLP-1 Receptor Component

The GLP-1 portion of amycretin operates through mechanisms now well-established from semaglutide and liraglutide research. GLP-1 receptor agonism produces three coordinated effects:

• Pancreatic insulin secretion: Glucose-dependent stimulation of beta cells, improving postprandial glycemic control without hypoglycemia risk under normal conditions
• Gut motility reduction: Slowing gastric emptying, which extends the physical sensation of fullness and blunts postprandial glucose excursions
• Central appetite suppression: GLP-1 receptors in the hypothalamus and brainstem reduce caloric intake through leptin-axis interactions and direct anorexigenic signaling

These mechanisms underpin semaglutide's clinical efficacy, which has been validated across the STEP trial program and confirmed in cardiovascular outcomes data from the SELECT trial [4].

The Amylin Receptor Component

The amylin receptor component is where amycretin breaks new ground compared to existing approved agents. Amylin receptors — technically CGRP/amylin receptor complexes comprising calcitonin receptor plus receptor activity-modifying proteins (RAMPs) — are densely expressed in the area postrema and nucleus tractus solitarius (NTS) of the brainstem. These are anatomically distinct from the primary GLP-1 receptor concentrations in the hypothalamus.

Amylin receptor activation produces effects that complement rather than duplicate GLP-1 signaling:

• Amplified gastric emptying delay: The amylin pathway slows gastric emptying through a different neural circuit than GLP-1, producing additive or synergistic delay
• Food reward reduction: The area postrema projection to the mesolimbic dopamine system means amylin signaling can blunt hedonic eating and food-seeking behavior — the craving dimension of obesity that GLP-1 agonism addresses less directly
• Satiety signal integration: The NTS integrates peripheral satiety signals from vagal afferents; amylin receptor activation in this region amplifies those signals centrally

The Pramlintide Precedent

The clinical validity of amylin receptor agonism is not speculative — it was established by pramlintide (Symlin), an FDA-approved amylin analog since 2005 used adjunctively with insulin in Type 1 and Type 2 diabetes. Pramlintide demonstrated meaningful postprandial glucose reduction and modest weight loss (2–3 kg) at approved doses. The limitation was its short half-life requiring multiple daily injections and subcutaneous delivery. Amycretin's amylin component incorporates structural modifications (similar to the fatty acid conjugation approach used in semaglutide) to achieve the once-weekly oral pharmacokinetic profile.

The synergy hypothesis — that GLP-1 + amylin receptor co-activation produces greater-than-additive appetite suppression — was supported by preclinical data showing that combination treatment in rodent models exceeded either monotherapy [5]. The Phase 2 human data now provides clinical evidence that this synergy translates across species.

The pivotal Phase 2 data for amycretin was published in NEJM Evidence in 2024, representing what many obesity researchers consider the most significant weight loss trial result since tirzepatide's SURMOUNT data [2]. Here is a detailed breakdown of the trial design and outcomes.

Trial Design (NCT05929976)

• Population: 338 adults with BMI ≥27 kg/m² (overweight or obese), without Type 2 diabetes
• Duration: 36 weeks of active treatment
• Intervention: Oral amycretin once weekly vs placebo, with dose escalation protocol
• Primary endpoint: Percent change in body weight from baseline to Week 36
• Setting: Multi-center Phase 2 randomized controlled trial, Novo Nordisk-sponsored

Primary Results

The primary endpoint results were unambiguous: oral amycretin produced a mean body weight reduction of 22.0% at 36 weeks, versus 4.7% with placebo — a treatment difference of approximately 17.3 percentage points. This effect size is exceptional for a 36-week trial, particularly considering that:

• Semaglutide 2.4mg SC (STEP-1 trial) achieved 14.9% mean weight reduction over 68 weeks
• Tirzepatide 15mg SC (SURMOUNT-1) achieved 22.5% over 72 weeks
• Amycretin matched tirzepatide's efficacy at roughly half the treatment duration

Secondary Endpoints: Responder Analysis

The responder data is equally compelling for understanding the population-level impact:

• 73% of amycretin participants achieved ≥10% body weight loss (vs ~20% placebo)
• 38% achieved ≥20% body weight loss — a threshold often described as "transformative" in obesity medicine
• Waist circumference, blood pressure, and fasting lipids all showed significant improvements vs placebo

Tolerability Profile

The GI side effect profile was consistent with GLP-1 receptor agonist class effects. Nausea was reported in approximately 45% of participants (vs ~15% placebo), and vomiting in approximately 28%. Discontinuation rates due to GI adverse events were comparable to semaglutide clinical programs. Notably, no amycretin-specific safety signals emerged beyond what would be expected from the GLP-1 and amylin receptor agonist classes individually.

The Oral Formulation Significance

Perhaps the most strategically significant aspect of these results is that they were achieved with an oral once-weekly tablet — not a subcutaneous injection. The oral semaglutide formulation (Rybelsus) requires daily dosing, specific fasting requirements, and has achieved only ~15% of the weight loss efficacy of injectable semaglutide at equivalent timepoints. Amycretin's oral formulation appears to overcome the bioavailability challenges that have historically limited oral peptide development, potentially representing a breakthrough in delivery technology as much as in mechanism.

Understanding amycretin's position in the therapeutic landscape requires a clear-eyed comparison with the existing and pipeline agents. These are not interchangeable drugs — each targets a distinct receptor profile with different downstream consequences beyond the shared goal of body weight reduction.

Semaglutide (GLP-1R Agonist Only)

Semaglutide remains the gold standard by which all subsequent agents are measured, for two reasons: its weight loss efficacy (15% mean in STEP-1) was transformative when published, and it is the only weight loss agent with proven cardiovascular outcomes data. The SELECT trial demonstrated a 20% relative risk reduction in major adverse cardiovascular events in adults with obesity but without diabetes [4]. No other weight loss peptide has replicated this with dedicated cardiovascular outcomes data. Amycretin has not yet been tested in a cardiovascular outcomes trial.

Tirzepatide (GLP-1R + GIPR Dual Agonist)

Tirzepatide extended the efficacy ceiling by adding GIP receptor agonism to GLP-1 receptor agonism. The GIP mechanism contributes to beta cell protection and insulin sensitivity through pathways distinct from GLP-1, and the SURMOUNT-1 data showing 22.5% weight reduction at maximum dose validated the dual-agonist approach clinically [3]. Tirzepatide's advantage over semaglutide appears to be roughly 7–8 percentage points of additional weight loss at comparable timepoints.

Retatrutide (GLP-1R + GIPR + GCGR Triple Agonist)

Retatrutide adds glucagon receptor (GCGR) agonism to the GLP-1/GIP dual combination. The glucagon component increases basal metabolic rate and hepatic fat mobilization — a fundamentally different mechanism from appetite suppression. Phase 2 data showed -24.2% weight reduction, the highest published figure for any weight loss peptide [6]. The trade-off is that glucagon receptor agonism can elevate blood glucose, requiring careful titration in patients with metabolic disease.

Amycretin (GLP-1R + Amylin Receptor Dual Agonist): The Unique Position

Amycretin's mechanism is uniquely positioned among this group. Rather than stacking additional metabolic rate modifiers (GIP, glucagon), amycretin targets the neurological reward and satiety circuitry more comprehensively than any single-receptor agent. The amylin component specifically addresses food reward, craving, and hedonic eating behaviors through the area postrema-mesolimbic dopamine axis — a pathway that purely metabolic agents leave largely unaddressed. For the significant subset of patients with obesity whose eating behavior is driven by food cravings and reward dysregulation rather than simple caloric imbalance, this distinction may translate to meaningfully better real-world outcomes. Additionally, the oral formulation addresses one of the most significant adherence barriers in current obesity pharmacotherapy.

To fully understand amycretin, it helps to understand cagrilintide — the amylin receptor agonist component that Novo Nordisk has been developing both as a standalone agent and in fixed-ratio combination with semaglutide under the name CagriSema.

Cagrilintide is a long-acting amylin analog engineered with a C20 fatty diacid attachment (similar structural approach to semaglutide) that extends its half-life to enable once-weekly subcutaneous dosing. In the Phase 1/2 study published in The Lancet in 2021, concomitant administration of cagrilintide and semaglutide produced weight loss numerically superior to either agent alone, establishing proof-of-concept for the amylin + GLP-1 combination [1].

CagriSema (Fixed-Ratio Combination) vs Amycretin (Fusion Molecule)

There is a critical distinction between these two approaches:

• CagriSema: Two separate molecules (cagrilintide + semaglutide) co-administered in a fixed-ratio injection. Currently in Phase 3 REDEFINE trials, showing approximately 22.7% weight loss. Still requires weekly subcutaneous injection.
• Amycretin: A single fusion molecule designed from the ground up to activate both receptor systems, formulated as an oral tablet. The molecular fusion design enables the oral bioavailability that co-administration of two separate peptides cannot achieve.

For researchers interested in the amylin receptor agonism component specifically, cagrilintide is the most advanced and well-characterized standalone amylin analog. Modified Aminos currently carries cagrilintide as a research peptide — one of the few domestic US suppliers offering this compound with documented COA data — allowing investigation of the amylin receptor pathway independent of the GLP-1 component.

Amycretin's oral formulation represents a genuine inflection point in obesity pharmacology — not just because of the weight loss numbers, but because it demonstrates that oral delivery of complex dual-agonist peptides is pharmacologically achievable. That proof-of-concept will accelerate an already extraordinarily active pipeline.

The Oral Peptide Frontier

Oral bioavailability has historically been the limiting factor for peptide therapeutics. The success of amycretin's oral formulation will drive significant investment in absorption-enhancing excipients, enteric coating technologies, and peptide engineering strategies that protect against gastrointestinal proteolysis — making the oral peptide pipeline one of the most competitive spaces in drug development through 2030.

Emerging Mechanisms Beyond GLP-1

• GLP-1/NPY2R dual agonists: Neuropeptide Y2 receptor agonism in early development; NPY2R governs energy homeostasis through circuits complementary to both GLP-1 and amylin pathways
• Muscle-sparing amylin analogs: A significant concern with aggressive weight loss is lean mass reduction; next-generation amylin-derived compounds are being engineered to preferentially target adipose mobilization while preserving skeletal muscle
• Combination cardiometabolic agents: GLP-1 agonism combined with PCSK9 inhibition or SGLT2 inhibition for comprehensive cardiometabolic risk reduction beyond weight loss alone
• GLP-1/glucagon/FGF21 triple agonists: Fibroblast growth factor 21 adds hepatoprotective properties relevant to NASH/MAFLD, extending the therapeutic footprint of multi-agonist peptides

As of 2026, the peptide pipeline for obesity management is arguably the most productive and well-funded drug development area in pharmaceutical history. With multiple mechanisms now clinically validated and oral delivery proven achievable, the trajectory from the next 5 years may produce efficacy and convenience profiles that make current approved agents look like first-generation tools. Amycretin, if Phase 3 data holds, will be at the center of that transformation.

The following is provided for research and educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before considering any pharmacological intervention.

GI Adverse Events (Class Effect)

The most common adverse events with amycretin in Phase 2 were gastrointestinal, consistent with the GLP-1 receptor agonist class. Nausea was reported in approximately 45% of participants, vomiting in approximately 28%, and constipation in approximately 20%. These effects were predominantly early in treatment and attenuated with continued dosing following the standard dose-escalation protocol. Discontinuation rates due to GI events were comparable to semaglutide clinical programs — approximately 5–8% of participants.

Hypoglycemia Risk

GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner, meaning hypoglycemia risk in individuals without diabetes and not on concurrent insulin or sulfonylurea therapy is low. No significant hypoglycemia signal was observed in the amycretin Phase 2 trial in the non-diabetic population studied.

Thyroid C-Cell Class Warning

GLP-1 receptor agonists as a class carry an FDA-required warning regarding thyroid C-cell tumors based on rodent studies. While no human cases have been confirmed causally linked to GLP-1 agonism across the extensive semaglutide and liraglutide clinical programs, the class warning applies to amycretin by mechanism. Individuals with personal or family history of medullary thyroid carcinoma or MEN2 syndrome should be excluded from GLP-1 receptor agonist therapy.

Pancreatitis

Acute pancreatitis is a rare but reported adverse event across the GLP-1 agonist class. The absolute risk is low (approximately 0.1–0.3% in clinical trial populations), but patients with prior pancreatitis history are generally excluded from clinical trials and should exercise caution with this drug class.

Amycretin-Specific Safety Profile

Critically, the Phase 2 data revealed no additional safety signals specific to the amylin receptor agonism component beyond what would be anticipated from the established GLP-1 and amylin receptor agonist classes. The amylin pathway (validated through pramlintide clinical experience since 2005) does not introduce new organ toxicity profiles. The cardiovascular effects of amycretin's amylin component — mild reductions in blood pressure and heart rate — were consistent with published pramlintide data. Long-term safety data awaits Phase 3 and post-approval surveillance programs.